Kirsten Bouchelouche1, Jacek Capala. 1. PET and Cyclotron Unit, PET 3982 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. bouchelouche@mail.tele.dk
Abstract
PURPOSE OF REVIEW: The current treatment options for advanced urologic cancers demonstrate limited efficacy. To obtain optimal clinical results, there is a need for new, individualized, therapeutic strategies, which have only recently been applied to these malignancies. Nuclear medicine plays an important role in establishing imaging biomarkers necessary for personalized medicine. This review focuses on the current status of the 'image and treat' approach combining molecular imaging with targeted radionuclide therapy of urological malignancies RECENT FINDINGS: Tumor-specific targets in uro-oncology are showing promising results for development of personalized therapy using positron emission tomography/computed tomography (PET/CT) molecular imaging and radioimmunotherapy. The antibody cG250, which binds to carbonic anhydrase IX, is being evaluated as a radiolabeled imaging and therapeutic agent in clear-cell renal cell carcinoma. I-cG250 PET/CT has demonstrated excellent targeting of clear-cell renal cell carcinoma. Prostate-specific membrane antigen is a promising target for both PET/CT and radioimmunotherapy of prostate cancer. HER2 may be another potential target in bladder and prostate cancer. SUMMARY: Tumor-specific targets and biomarkers are being studied for PET/CT and radioimmunotherapy. This may lead to development of new therapeutic strategies. However, considerable investment in new research will be required for personalized medicine to be routinely used in uro-oncology.
PURPOSE OF REVIEW: The current treatment options for advanced urologic cancers demonstrate limited efficacy. To obtain optimal clinical results, there is a need for new, individualized, therapeutic strategies, which have only recently been applied to these malignancies. Nuclear medicine plays an important role in establishing imaging biomarkers necessary for personalized medicine. This review focuses on the current status of the 'image and treat' approach combining molecular imaging with targeted radionuclide therapy of urological malignancies RECENT FINDINGS:Tumor-specific targets in uro-oncology are showing promising results for development of personalized therapy using positron emission tomography/computed tomography (PET/CT) molecular imaging and radioimmunotherapy. The antibody cG250, which binds to carbonic anhydrase IX, is being evaluated as a radiolabeled imaging and therapeutic agent in clear-cell renal cell carcinoma. I-cG250 PET/CT has demonstrated excellent targeting of clear-cell renal cell carcinoma. Prostate-specific membrane antigen is a promising target for both PET/CT and radioimmunotherapy of prostate cancer. HER2 may be another potential target in bladder and prostate cancer. SUMMARY:Tumor-specific targets and biomarkers are being studied for PET/CT and radioimmunotherapy. This may lead to development of new therapeutic strategies. However, considerable investment in new research will be required for personalized medicine to be routinely used in uro-oncology.
Authors: E Oosterwijk; D J Ruiter; P J Hoedemaeker; E K Pauwels; U Jonas; J Zwartendijk; S O Warnaar Journal: Int J Cancer Date: 1986-10-15 Impact factor: 7.396
Authors: Peter M Smith-Jones; Shankar Vallabhajosula; Vincent Navarro; Diego Bastidas; Stanley J Goldsmith; Neil H Bander Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: M G Steffens; O C Boerman; P H de Mulder; W J Oyen; W C Buijs; J A Witjes; W J van den Broek; J C Oosterwijk-Wakka; F M Debruyne; F H Corstens; E Oosterwijk Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531
Authors: M R McDevitt; E Barendswaard; D Ma; L Lai; M J Curcio; G Sgouros; A M Ballangrud; W H Yang; R D Finn; V Pellegrini; M W Geerlings; M Lee; M W Brechbiel; N H Bander; C Cordon-Cardo; D A Scheinberg Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701
Authors: P M Smith-Jones; S Vallabahajosula; S J Goldsmith; V Navarro; C J Hunter; D Bastidas; N H Bander Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701
Authors: Ase M Ballangrud; Wei-Hong Yang; Stig Palm; Richard Enmon; Paul E Borchardt; Virginia A Pellegrini; Michael R McDevitt; David A Scheinberg; George Sgouros Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: Chaitanya R Divgi; Joseph A O'Donoghue; Sydney Welt; Jayne O'Neel; Ron Finn; Robert J Motzer; Achim Jungbluth; Eric Hoffman; Gerd Ritter; Steve M Larson; Lloyd J Old Journal: J Nucl Med Date: 2004-08 Impact factor: 10.057
Authors: Adrienne H Brouwers; Wilhelmina C A M Buijs; Egbert Oosterwijk; Otto C Boerman; Carola Mala; Pieter H M De Mulder; Frans H M Corstens; Peter F A Mulders; Wim J G Oyen Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: Adrienne H Brouwers; Julliëtte E M van Eerd; Cathelijne Frielink; Egbert Oosterwijk; Wim J G Oyen; Frans H M Corstens; Otto C Boerman Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057
Authors: Irina Velikyan; Thomas N Bulenga; Ramkumar Selvaraju; Mark Lubberink; Daniel Espes; Ulrika Rosenström; Olof Eriksson Journal: Am J Nucl Med Mol Imaging Date: 2015-01-15
Authors: Kirsten Bouchelouche; Scott T Tagawa; Stanley J Goldsmith; Baris Turkbey; Jacek Capala; Peter Choyke Journal: Semin Nucl Med Date: 2011-01 Impact factor: 4.446